Abstract
Summary
Anaplastic Lymphoma Kinase (ALK) gene, as a tyrosine kinase closely related to tumors, can be activated by translocation or mutation. Abnormal expression such as gene mutation, rearrangement and amplification can activate cell signal transduction in the body. Pathway, which regulates the growth, differentiation and migration of tumors. Tyrosine kinases are kinases that enzymatically catalyze the transfer of gamma phosphate groups from adenosine triphosphate to target proteins. They can catalyze the phosphorylation of protein tyrosine residues on a variety of substrates, and play an important role in cell growth, proliferation, and differentiation. The main oncology indications for tyrosine kinase inhibitors (TKI) include solid tumors and leukemia.
The global market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) include Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding and Chugai Pharmaceutical Co, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) by region & country, by Type, and by Application.
The ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ALK Tyrosine Kinase Inhibitors (ALK-TKIs).
Market Segmentation
By Company
Pfizer
Nuvartis
Takeda
Betta Pharma
Shouyao Holding
Chugai Pharmaceutical Co
Segment by Type:
Crizotinib
Alectinib
Ceritinib
Brigatinib
Lorlatinib
Ensartinib
CT-707
Segment by Application
Leukemia
Solid Tumor
Lung Cancer
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) include Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding and Chugai Pharmaceutical Co, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) by region & country, by Type, and by Application.
The ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ALK Tyrosine Kinase Inhibitors (ALK-TKIs).
Market Segmentation
By Company
Pfizer
Nuvartis
Takeda
Betta Pharma
Shouyao Holding
Chugai Pharmaceutical Co
Segment by Type:
Crizotinib
Alectinib
Ceritinib
Brigatinib
Lorlatinib
Ensartinib
CT-707
Segment by Application
Leukemia
Solid Tumor
Lung Cancer
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Product Introduction
1.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size Forecast
1.3 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Trends & Drivers
1.3.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Industry Trends
1.3.2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Drivers & Opportunity
1.3.3 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Challenges
1.3.4 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Players Revenue Ranking (2023)
2.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue by Company (2019-2024)
2.3 Key Companies ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Manufacturing Base Distribution and Headquarters
2.4 Key Companies ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Product Offered
2.5 Key Companies Time to Begin Mass Production of ALK Tyrosine Kinase Inhibitors (ALK-TKIs)
2.6 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Competitive Analysis
2.6.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ALK Tyrosine Kinase Inhibitors (ALK-TKIs) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Crizotinib
3.1.2 Alectinib
3.1.3 Ceritinib
3.1.4 Brigatinib
3.1.5 Lorlatinib
3.1.6 Ensartinib
3.1.7 CT-707
3.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type
3.2.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, by Type (2019-2030)
3.2.3 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Leukemia
4.1.2 Solid Tumor
4.1.3 Lung Cancer
4.1.4 Others
4.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application
4.2.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, by Application (2019-2030)
4.2.3 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Region
5.1.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Region (2019-2024)
5.1.3 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Region (2025-2030)
5.1.4 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
5.2.2 North America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
5.3.2 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
5.4.2 Asia Pacific ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
5.5.2 South America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
5.6.2 Middle East & Africa ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value
6.3 United States
6.3.1 United States ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
6.3.2 United States ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
6.4.2 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
6.5.2 China ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (%), 2023 VS 2030
6.5.3 China ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
6.6.2 Japan ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
6.7.2 South Korea ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
6.8.2 Southeast Asia ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value, 2019-2030
6.9.2 India ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Type (%), 2023 VS 2030
6.9.3 India ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Profile
7.1.2 Pfizer Main Business
7.1.3 Pfizer ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
7.1.4 Pfizer ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Recent Developments
7.2 Nuvartis
7.2.1 Nuvartis Profile
7.2.2 Nuvartis Main Business
7.2.3 Nuvartis ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
7.2.4 Nuvartis ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2019-2024)
7.2.5 Nuvartis Recent Developments
7.3 Takeda
7.3.1 Takeda Profile
7.3.2 Takeda Main Business
7.3.3 Takeda ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
7.3.4 Takeda ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2019-2024)
7.3.5 Betta Pharma Recent Developments
7.4 Betta Pharma
7.4.1 Betta Pharma Profile
7.4.2 Betta Pharma Main Business
7.4.3 Betta Pharma ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
7.4.4 Betta Pharma ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2019-2024)
7.4.5 Betta Pharma Recent Developments
7.5 Shouyao Holding
7.5.1 Shouyao Holding Profile
7.5.2 Shouyao Holding Main Business
7.5.3 Shouyao Holding ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
7.5.4 Shouyao Holding ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2019-2024)
7.5.5 Shouyao Holding Recent Developments
7.6 Chugai Pharmaceutical Co
7.6.1 Chugai Pharmaceutical Co Profile
7.6.2 Chugai Pharmaceutical Co Main Business
7.6.3 Chugai Pharmaceutical Co ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
7.6.4 Chugai Pharmaceutical Co ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2019-2024)
7.6.5 Chugai Pharmaceutical Co Recent Developments
8 Industry Chain Analysis
8.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Industrial Chain
8.2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Sales Model
8.5.2 Sales Channel
8.5.3 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer